{"id":815075,"date":"2025-02-19T16:21:30","date_gmt":"2025-02-19T21:21:30","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-report-financial-results-for-fourth-quarter-and-full-year-2024-after-market-close-on-february-26-2025\/"},"modified":"2025-02-19T16:21:30","modified_gmt":"2025-02-19T21:21:30","slug":"revolution-medicines-to-report-financial-results-for-fourth-quarter-and-full-year-2024-after-market-close-on-february-26-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-report-financial-results-for-fourth-quarter-and-full-year-2024-after-market-close-on-february-26-2025\/","title":{"rendered":"Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2024 After Market Close on February 26, 2025"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">REDWOOD CITY, Calif., Feb.  19, 2025  (GLOBE NEWSWIRE) &#8212; Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the fourth quarter and full year 2024 on Wednesday, February 26, 2025, after market close. At 4:30 p.m. ET that day (1:30 p.m. PT), members of Revolution Medicines\u2019 senior management team will host a webcast to discuss the financial results for the quarter and full year and provide an update on corporate progress.<\/p>\n<p align=\"justify\">To listen to the live webcast, or access the archived webcast, please visit:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=2Koe_tLqxJIV5vFBUQtAwoVkrVtpihsk-DUiuRSrfZaN3AHJHi88Af9Ua19Uv7_b1t3aAysrWY4pWhIBAQn5MY7gEh-ipHUNQc7qgI5ASgwZa6VeTZmUVd_zKOK-i66HcDDeoDSf5rE9_Ueyxm7asCP4aUNhdSGxJsjb_dDO_574KwZJF_efErhtuHb-fqoPCnLqWQorjvQFzWEdEXx2itS3EcexZzsb3SGwMgv2Eu_t3DI-WJ6Oz3tuaY2gf62lnxRE8f25JEsNrNDyI_B5icVPspRz9r6Am688oUpK-CnDjSccOGPcb0YH8J8_s-VaGTgnBiZAy80-DmkhbDi1cYPgdwVsJCp6u081KGE5JRzUsD8VUlPWrvCGCL9PXO11\" rel=\"nofollow\" target=\"_blank\">https:\/\/ir.revmed.com\/events-and-presentations<\/a>. Following the live webcast, a replay will be available on the company\u2019s website for at least 14 days.<\/p>\n<p align=\"justify\">\n        <strong>About Revolution Medicines, Inc.<br \/><\/strong>Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company\u2019s R&amp;D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company\u2019s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; and zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor, are currently in clinical development. Additional development opportunities in the company\u2019s pipeline focus on RAS(ON) mutant-selective inhibitors, including RMC-5127 (G12V), RMC-0708 (Q61H) and RMC-8839 (G13C). For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_q_LDY3jyMOmyvZxXotqJc7DMQLoWs4ZfP_OZukLVbSjHCEYxxiLMmCT65A8L8CaarNggCj4UupPnkgM8gp0P3esOqyrXpTaWhPETGHxGX16vCXZJo_PNX_EwxoBjENMyy93VoFW1uixCDcYoOrxrBC8V99mo6jsTYRyuHK3Ff42w1PVvU-ROZ_V6d6pC3H95-Y3n_hUj0XR4eWwKS7D53fD_lNe2kmHyvSlzUV81JY=\" rel=\"nofollow\" target=\"_blank\"><u>www.revmed.com<\/u><\/a>\u00a0and follow us on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=rpKlOzLin-Lx7jU0Ra-CWvOhBd9755yBDj1HNtzftJFyKX0OQyeGkhR7pvRoNPzA1wzFHqowv0NLlfW6mI9vkzt2TuxBSHWPsXZscJBodZPERCBG92FNmNPNFa_z3HgreWVXoZXUJ1Z3u1BP248sp8iqIOBZJ0XzlFwJUe980kQHNWYXNobaV03PNW_VaHekYRIH5W59EFJ4GM9hToEwPSeSV88g0u-HFD_4xduWRVb1AOXFL445jxkIUglmy7IWDQMKYHbJKzShdAOmY9GQkQ==\" rel=\"nofollow\" target=\"_blank\"><u>LinkedIn<\/u><\/a>.<\/p>\n<p>\n        <strong>Revolution Medicines Media &amp; Investor Contact:<\/strong><br \/>\n        <br \/>media@revmed.com<br \/>investors@revmed.com<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MTEzNCM2NzU2NzU0IzIxOTQwMzQ=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZGFiMjk1OGQtMWE4NS00ZWFjLThmOGUtZjYwYjhmMzViZGZkLTEyMDU1ODc=\/tiny\/Revolution-Medicines-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>REDWOOD CITY, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) &#8212; Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the fourth quarter and full year 2024 on Wednesday, February 26, 2025, after market close. At 4:30 p.m. ET that day (1:30 p.m. PT), members of Revolution Medicines\u2019 senior management team will host a webcast to discuss the financial results for the quarter and full year and provide an update on corporate progress. To listen to the live webcast, or access the archived webcast, please visit:\u00a0https:\/\/ir.revmed.com\/events-and-presentations. Following the live webcast, a replay will be available on the company\u2019s website for at least 14 &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-report-financial-results-for-fourth-quarter-and-full-year-2024-after-market-close-on-february-26-2025\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2024 After Market Close on February 26, 2025&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-815075","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2024 After Market Close on February 26, 2025 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-report-financial-results-for-fourth-quarter-and-full-year-2024-after-market-close-on-february-26-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2024 After Market Close on February 26, 2025 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"REDWOOD CITY, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) &#8212; Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the fourth quarter and full year 2024 on Wednesday, February 26, 2025, after market close. At 4:30 p.m. ET that day (1:30 p.m. PT), members of Revolution Medicines\u2019 senior management team will host a webcast to discuss the financial results for the quarter and full year and provide an update on corporate progress. To listen to the live webcast, or access the archived webcast, please visit:\u00a0https:\/\/ir.revmed.com\/events-and-presentations. Following the live webcast, a replay will be available on the company\u2019s website for at least 14 &hellip; Continue reading &quot;Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2024 After Market Close on February 26, 2025&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-report-financial-results-for-fourth-quarter-and-full-year-2024-after-market-close-on-february-26-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-19T21:21:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MTEzNCM2NzU2NzU0IzIxOTQwMzQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolution-medicines-to-report-financial-results-for-fourth-quarter-and-full-year-2024-after-market-close-on-february-26-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolution-medicines-to-report-financial-results-for-fourth-quarter-and-full-year-2024-after-market-close-on-february-26-2025\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2024 After Market Close on February 26, 2025\",\"datePublished\":\"2025-02-19T21:21:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolution-medicines-to-report-financial-results-for-fourth-quarter-and-full-year-2024-after-market-close-on-february-26-2025\\\/\"},\"wordCount\":263,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolution-medicines-to-report-financial-results-for-fourth-quarter-and-full-year-2024-after-market-close-on-february-26-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM2MTEzNCM2NzU2NzU0IzIxOTQwMzQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolution-medicines-to-report-financial-results-for-fourth-quarter-and-full-year-2024-after-market-close-on-february-26-2025\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolution-medicines-to-report-financial-results-for-fourth-quarter-and-full-year-2024-after-market-close-on-february-26-2025\\\/\",\"name\":\"Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2024 After Market Close on February 26, 2025 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolution-medicines-to-report-financial-results-for-fourth-quarter-and-full-year-2024-after-market-close-on-february-26-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolution-medicines-to-report-financial-results-for-fourth-quarter-and-full-year-2024-after-market-close-on-february-26-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM2MTEzNCM2NzU2NzU0IzIxOTQwMzQ=\",\"datePublished\":\"2025-02-19T21:21:30+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolution-medicines-to-report-financial-results-for-fourth-quarter-and-full-year-2024-after-market-close-on-february-26-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolution-medicines-to-report-financial-results-for-fourth-quarter-and-full-year-2024-after-market-close-on-february-26-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolution-medicines-to-report-financial-results-for-fourth-quarter-and-full-year-2024-after-market-close-on-february-26-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM2MTEzNCM2NzU2NzU0IzIxOTQwMzQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM2MTEzNCM2NzU2NzU0IzIxOTQwMzQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolution-medicines-to-report-financial-results-for-fourth-quarter-and-full-year-2024-after-market-close-on-february-26-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2024 After Market Close on February 26, 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2024 After Market Close on February 26, 2025 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-report-financial-results-for-fourth-quarter-and-full-year-2024-after-market-close-on-february-26-2025\/","og_locale":"en_US","og_type":"article","og_title":"Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2024 After Market Close on February 26, 2025 - Market Newsdesk","og_description":"REDWOOD CITY, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) &#8212; Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the fourth quarter and full year 2024 on Wednesday, February 26, 2025, after market close. At 4:30 p.m. ET that day (1:30 p.m. PT), members of Revolution Medicines\u2019 senior management team will host a webcast to discuss the financial results for the quarter and full year and provide an update on corporate progress. To listen to the live webcast, or access the archived webcast, please visit:\u00a0https:\/\/ir.revmed.com\/events-and-presentations. Following the live webcast, a replay will be available on the company\u2019s website for at least 14 &hellip; Continue reading \"Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2024 After Market Close on February 26, 2025\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-report-financial-results-for-fourth-quarter-and-full-year-2024-after-market-close-on-february-26-2025\/","og_site_name":"Market Newsdesk","article_published_time":"2025-02-19T21:21:30+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MTEzNCM2NzU2NzU0IzIxOTQwMzQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-report-financial-results-for-fourth-quarter-and-full-year-2024-after-market-close-on-february-26-2025\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-report-financial-results-for-fourth-quarter-and-full-year-2024-after-market-close-on-february-26-2025\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2024 After Market Close on February 26, 2025","datePublished":"2025-02-19T21:21:30+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-report-financial-results-for-fourth-quarter-and-full-year-2024-after-market-close-on-february-26-2025\/"},"wordCount":263,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-report-financial-results-for-fourth-quarter-and-full-year-2024-after-market-close-on-february-26-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MTEzNCM2NzU2NzU0IzIxOTQwMzQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-report-financial-results-for-fourth-quarter-and-full-year-2024-after-market-close-on-february-26-2025\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-report-financial-results-for-fourth-quarter-and-full-year-2024-after-market-close-on-february-26-2025\/","name":"Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2024 After Market Close on February 26, 2025 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-report-financial-results-for-fourth-quarter-and-full-year-2024-after-market-close-on-february-26-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-report-financial-results-for-fourth-quarter-and-full-year-2024-after-market-close-on-february-26-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MTEzNCM2NzU2NzU0IzIxOTQwMzQ=","datePublished":"2025-02-19T21:21:30+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-report-financial-results-for-fourth-quarter-and-full-year-2024-after-market-close-on-february-26-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-report-financial-results-for-fourth-quarter-and-full-year-2024-after-market-close-on-february-26-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-report-financial-results-for-fourth-quarter-and-full-year-2024-after-market-close-on-february-26-2025\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MTEzNCM2NzU2NzU0IzIxOTQwMzQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MTEzNCM2NzU2NzU0IzIxOTQwMzQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-report-financial-results-for-fourth-quarter-and-full-year-2024-after-market-close-on-february-26-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2024 After Market Close on February 26, 2025"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/815075","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=815075"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/815075\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=815075"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=815075"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=815075"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}